Zydus Lifesciences Ltd
Zydus Lifesciences Q4 FY26: Capex ₹1,500 Cr
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #54 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Zydus Lifesciences Ltd Q4 FY26 key numbers
- Revenue
- US generic business forecasted to maintain a base around $300-310 million with some erosion due to competition but balanced by new product launches.
As stated in Zydus Lifesciences Ltd's Q4 FY26 earnings call transcript · published 24 May 2026. Reported figures, not investment advice.
The short version
India business expected to outperform market by 200-400 basis points, driven by innovative portfolio, strong brands, and therapy focus. US business: Expected single-digit growth next year despite no Revlimid revenue; growth driven by base business volume, new product launches, and specialty portfolio scaling up.
From Zydus Lifesciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business expected to outperform market by 200-400 basis points, driven by innovative portfolio, strong brands, and therapy focus.
- Specialty business in the US (505(b)(2), rare disease portfolio) is currently small but expected to scale up significantly from FY28 onwards.
- US generic business forecasted to maintain a base around $300-310 million with some erosion due to competition but balanced by new product launches.
- International markets growing strongly at 40%+, driven by broad geographic expansion and robust portfolio launches; growth momentum expected to continue.
- Biosimilars business in India is a meaningful contributor; global scale-up of biologics and biosimilars anticipated by FY29-FY30.
- MedTech and CDMO businesses are building platforms with meaningful contributions expected over 3-4 years.
2 more points from Zydus Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zydus Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 capex is planned around ₹1,500 crores, reflecting multiple expansion initiatives.
- Quarterly depreciation is approximately ₹550 crores, influenced by capitalized licensing fees related to Mirabegron, which will cease around September 2027.
- Capital allocation priorities include building new capabilities, especially in Specialty and 505(b)(2) portfolios, with bolt-on acquisitions expected to continue.
- Ongoing investments to scale the Specialty business and international markets are emphasized for sustained growth.
- Digital transformation with advanced analytics, automation, and AI is part of operational efficiency improvements.
- Investment in commercialization of Saroglitazar (Saro) includes an additional $70 million planned for FY27.
2 more points from Zydus Lifesciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zydus Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Zydus Lifesciences Ltd said on order book & pipeline — free account, 30 seconds.
Zydus Lifesciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.6K Cr, net profit ₹1.3K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zydus Lifesci.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zydus Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zydus Lifesciences Ltd Q4 FY26 results?
India business expected to outperform market by 200-400 basis points, driven by innovative portfolio, strong brands, and therapy focus. US business: Expected single-digit growth next year despite no Revlimid revenue; growth driven by base business volume, new product launches, and specialty portfolio scaling up.
What is Zydus Lifesciences Ltd share price analysis?
Zydus Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 23.3 with a market cap of ₹113,237 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zydus Lifesciences Ltd planning capital expenditure?
FY27 capex is planned around ₹1,500 crores, reflecting multiple expansion initiatives.
Keep Zydus Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.